BLUE - Why Bluebird Bio Stock Is Flying Today
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts the stock in prime short-squeeze territory.
Bluebird's stock is heavily shorted because the company is unprofitable, and it may not have enough cash to cover its expenses over the next 12 months. Its trailing-12-month operating costs are above $497.4 million, and its cash and equivalents only total around $211.6 million.
Nonetheless, in June the company's stock soared by nearly 39.4% thanks to a pair of unanimous favorable votes from regulators on a nonbinding advisory committee at the Food and Drug Administration (FDA). The committee voted that the biotech's candidate gene therapies for beta thalassemia and cerebral adrenoleukodystrophy (CALD) were both likely to be safe and effective enough to justify their use.
For further details see:
Why Bluebird Bio Stock Is Flying Today